Introduction
The development of an efficient and safe gene transfer and expression system is a main requirement for human gene therapy. There are various kinds of gene delivery methods including virus, cationic liposomes, and cationic polymers. Currently, viral vectors are the most efficient way to deliver genes to cells. However, the clinical applications of virus vectors are limited because of the intrinsic properties of viruses such as immunogenecity, random integration into chromosomal DNA, inefficiency of large preparation, possible oncogenic rearrangement, and the size limit of DNA. 1 Therefore, to apply viral vectors to clinical gene therapy settings, they should be improved in terms of safety. Another approach of somatic gene delivery is to use nonviral carriers. Nonviral carriers are composed of cationic liposomes and cationic polymers. 2 These nonviral carriers have suffered from low gene delivery efficiency. In terms of safety, nonviral gene carriers have excellent characteristics such as low cytotoxicity, low immunogenecity, and nonintegration to host chromosomal DNA. Therefore, low immunogenecity and low cytotoxicity of the nonviral carriers enable us to administrate the gene/ carrier complexes repeatedly and overcome their low gene delivery efficiency.
Previously, we developed a gene carrier, water-soluble lipopolymer (WSLP), in which cholesterol was conjugated to low molecular weight PEI (1800 Da). 3 WSLP has excellent characteristics as a gene carrier. PEI in WSLP has many protonation sites, which may cause the influx of chloride ions into the endosomes. As a result of the proton sponge effect of PEI, endosomes are broken to release their internal contents. 2 Therefore, WSLP can deliver pDNA without the requirement of any colipid as a liposomal compartment. In addition, WSLP has high transfection efficiency to various types of cells. 3, 4 Furthermore, WSLP has low cytotoxicity and, therefore, it might not cause severe toxicity to the cells. Our previous report showed that WSLP showed low cytotoxicity to 293T cells, CT26 cells, MIN6 cells, and A7R5 cells. [3] [4] [5] In addition, the myocardium transfection by WSLP was evaluated previously. It has longer and higher gene expression than naked DNA and PEI. 5 Another important consideration for gene therapy is the construction of an effective therapeutic gene. Currently, VEGF is the most effective therapeutic gene for the neovascularization. 6 Previously it was reported that both VEGF and its receptors were upregulated in ischemic tissues. 7 Therefore, it was suggested that ischemia is necessary for VEGF to exert its effects. 8 However, Springer et al 9 proved that exogenously delivered VEGF could exert a physiological effect in normal, nonischemic tissue. This suggested that VEGF expression must be carefully modulated. In addition, unregulated continuous expression of VEGF is associated with the formation of endothelial cell-derived intramural vascular tumors. 10 Here we propose that hypoxia-regulated VEGF expression can reduce the dangerous side effect of unregulated VEGF expression. The erythropoietin (Epo) enhancer was previously reported to enhance the promoter activity specifically under hypoxia condition. [11] [12] [13] These studies showed that the Epo enhancer induced reporter gene expression in various cell lines under hypoxia condition, suggesting that the Epo enhancer can induce therapeutic gene expression irrespective of cell types. Therefore, the Epo enhancer may be applied for the hypoxia-regulated therapeutic gene expression for ischemic heart gene therapy.
In this study, we constructed the hypoxia-regulated VEGF plasmid using the Epo enhancer. The efficiency of the pEpo-SV-VEGF/WSLP complex was evaluated by various methods in vitro and in vivo. The results suggested that the hypoxia-inducible VEGF gene therapy system is effective and safe, which may be useful for the gene therapy of ischemic heart disease.
Results

Construction of plasmids
pSV-Luc was purchased from Promega. The Epo enhancer was synthesized chemically. A BamHI or XbaI site was introduced at each end of the Epo enhancer, respectively. Two copies of the Epo enhancers were inserted at the BglII site upstream of the SV40 minimal promoter of pSV-Luc, producing pEpo-SV-Luc (Figure 1 ). The human VEGF 165 cDNA was amplified by PCR using pSG5-VEGF as a template to introduce HindIII and XbaI at each end of the cDNA, respectively. To construct pSV-VEGF, the PCR product was inserted to the pSV-Luc vector at the HindIII and XbaI sites after the deletion of the luciferase gene ( Figure 1 ). Two copies of the Epo enhancers were inserted at a BglII site upstream of the Simian Virus 40 (SV40) minimal promoter, producing pEpo-SV-VEGF (Figure 1 ). Generally, an enhancer can induce promoter activity irrespective of its position. To evaluate the effect of the downstream-located Epo enhancer in gene expression, we constructed pSV-VEGF-Epo. To construct pSV-VEGF-Epo, two copies of the Epo enhancers were inserted at the BamHI site downstream of the SV40 poly(A) signal (Figure 1 ). The constructions of the plasmids were confirmed by a restriction enzyme study.
In vitro transfection and luciferase assay
To confirm that the Epo enhancer induces gene expression under hypoxia condition, luciferase assay was performed. The WSLP/pSV-Luc or WSLP/pEpo-SV-Luc complex was prepared at a 40/1 N/P ratio, since WSLP showed the best transfection efficiency in vitro at a 40/1 N/P ratio in the previous report. 5 The complexes were transfected to human embryonic 293 cells and the cells were incubated under normoxia (pO 2 , 152 mmHg) or hypoxia (pO 2 , 7.6 mmHg) condition for 24 h. It was previously reported that 293 cells did not secrete detectable amounts of VEGF.
14 In addition, hypoxiainducible factor (HIF) 1 is accumulated in 293 cells under hypoxia condition, which is a key transcription factor for the regulation of hypoxia-responsive gene expression. 13 After the incubation, luciferase activity was measured. As a result, pEpo-SV-Luc showed approximately three times higher gene expression under hypoxia condition than under normoxia condition ( Figure 2 ). However, pSV-Luc did not show this effect (Figure 2 ). 
In vitro transfection and VEGF expression assay
To evaluate the level of VEGF expression, pSV-VEGF, pEpo-SV-VEGF, and pSV-VEGF-Epo were transfected to 293 cells using WSLP as a gene carrier. pSV-Luc was transfected as a negative control. The plasmid/WSLP complex was prepared at a 40/1 N/P ratio. HIF-1 was previously found to be induced by CoCl 2 treatment. β-Actin
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After the transfection of the plasmid/WSLP complexes, the cells were incubated under normoxia or hypoxia condition for 24 or 48 h. The medium was harvested and enzyme-linked immunosorbent assay (ELI-SA) was performed to measure the level of the secreted VEGF protein. After 24 h of incubation, pEpo-SV-VEGF expressed approximately three times more VEGF proteins under hypoxia condition than under normoxia condition (Figure 4a ). After 48 h of incubation, approximately 10 times more VEGF proteins were secreted to the medium under hypoxia condition than under normoxia condition. Without the Epo enhancer, pSV-VEGF did not enhance the production of VEGF under hypoxia condition (Figure 4b) . Therefore, the induction of VEGF expression was specific for hypoxic cells.
It was previously reported that 293 cells did not express a detectable amount of VEGF.
14 Therefore, the endogenous VEGF mRNA was not detected in RT-PCR (Figure 3a-d) and the basal level of VEGF in ELISA was very low (Figure 4a and b) .
In vitro endothelial cell proliferation assay
To measure the activity of the VEGF protein produced by the transfected cells, the in vitro endothelial cell proliferation assay was performed. Our aim was to show that pEpo-SV-VEGF produces more VEGF proteins and enhances the proliferation of the endothelial cells. The 293 cells were cultured in F-12k medium without endothelial cell growth supplements (ECGS). We transfected the pEpo-SV-VEGF/WSLP or pSV-VEGF/WSLP complex into 293 cells, and incubated the cells under normoxia and hypoxia condition for 24 or 48 h. The pSVLuc/WSLP complex was transfected as a negative control. After the incubation under hypoxia or normoxia conditions, the culture medium was collected and human umbilical vascular endothelial cells (HUVEC) were incubated in the medium. The relative proliferations of the cells were measured by MTT assay after 5 days of incubation with the media. The results showed that the proliferation rate of HUVEC was much faster in the medium from the 293 cells transfected with pEpo-SV-VEGF and incubated under hypoxia condition than in the other media (Figure 5a and b) . These results suggested that the VEGF protein, which was produced from the pEpo-SV-VEGF-transfected and hypoxia-incubated cell, was able to enhance the proliferation of the endothelial cells.
In vivo VEGF gene expression in the rabbit ischemic myocardium model
We injected the plasmids/WSLP complex into the rabbit myocardium. The ischemic myocardium model was produced by the ligation of the circumflex artery. Since the previous report showed that the pDNA/WSLP complex showed the highest transfection efficiency into myocardium at a 10/1 N/P ratio, 5 the pEpo-SV-VEGF or pSV-VEGF was complexed with WSLP at a 10/1 N/P ratio and injected into the myocardium. The VEGF expression level in the myocardium was evaluated by ELISA. The results showed that the expression level of VEGF by pEpo-SV-VEGF in ischemic myocardium was three times higher than in normal myocardium ( Figure 6 ). Also, pSV-VEGF could not induce VEGF expression in normal and ischemic myocardium ( Figure  6 ). The control showed the basal level expression of VEGF ( Figure 6 ). It has been known that the expression of endogenous VEGF is controlled by its own hypoxiadriven regulatory system. [15] [16] [17] [18] [19] Therefore, this basal expression of the endogenous VEGF gene is not unregulated and continuous.
Discussion
We have shown that the pEpo-SV-VEGF/WSLP complex induced VEGF expression specifically in hypoxic cells (Figure 3a) . The SV40 promoter without the Epo enhancer was unable to induce the gene expression in the presence of cobalt (Figure 3a and b) . It was previously reported that HIF-1 transcription factor was activated by cobalt as well as hypoxia. 13 Therefore, these results indicated that the induction of VEGF expression was mediated by HIF-1 transcription factor. In addition, the induction by the Epo enhancer depended on the position of the Epo enhancer. This induction of VEGF expression increased endothelial cell proliferation (Figure 5a and b) . In addition, the Epo enhancer induced VEGF expression in ischemic myocardium ( Figure 6 ). These results showed that a hypoxiaresponsive element in the Epo enhancer regulated the gene expression in normal or ischemic myocardium.
Natural expression of VEGF is controlled by its own hypoxia-driven regulatory system at two different levels: transcription and translation. The VEGF promoter has a hypoxia-responsive element that binds to HIF-1 and activates the transcription of the gene under hypoxia condition.
15-17 After transcription, the VEGF mRNA is stabilized by cooperation of multiple RNA elements such as coding regions and 5 0 -and 3 0 -untranslated regions (UTRs), resulting in an increase of the translation rate . 18, 19 Several hypoxia-regulated genes including Epo have hypoxia-responsive elements in their promoters and enhancers. By employing the Epo enhancer for the regulation of the VEGF gene, we mimicked the natural regulation for VEGF expression. Recently, hypoxiaregulated gene expression in the mouse ischemic heart model was reported using hypoxia-responsive element by adeno-associated virus-mediated gene transfer. 20 In addition, the Epo-enhancer-mediated induction of the VEGF gene was proven in a rabbit ischemic heart model in the present study. Therefore, these results indicate that a hypoxia-regulated gene expression system is applicable to ischemic tissue in vivo to minimize nonspecific gene expression. Furthermore, our nonviral carrier system has advantages. First, WSLP has higher transfection efficiency and longer gene expression in myocardium than naked DNA and PEI. 5 It was previously suggested that the cholesterol group in WSLP enhanced the transfection using cellular cholesterol uptake pathway such as LDL Hypoxia-inducible gene therapy M Lee et al receptor. 5 Second, WSLP has low cytotoxicity to the cells. It was previously proved that WSLP has low cytotoxicity to 293 cells, 3 CT26 colon cancer cells, 3 mouse insulinoma MIN6 cells, 4 and A7R5 smooth muscle cells. 5 Third, WSLP does not integrate the plasmid into the host chromosome, which minimizes possible oncogene activation or tumor suppressor gene inactivation. In addition, WSLP does not induce a cellular immune response.
In summary, we designed a nonviral gene delivery system using the hypoxia-regulated VEGF expression plasmid and WSLP. This pEpo-SV-VEGF/WSLP system is effective in that it induces VEGF expression specifically in ischemic tissue, and is safe since WSLP has low toxicity and low immunogenicity. Therefore, the pEpo-SV-VEGF/WSLP gene therapy system may be helpful in eventually treating ischemic heart disease.
Materials and methods
Plasmid construction
pSV-Luc was purchased from Promega (Madison, WI, USA). The Epo enhancer was chemically synthesized. The sequence of the Epo enhancer is as follows: 5 0 -GCCCTACGTGCTGTCTCACACAGCCTGTCTGACCT CTCGACCTACCGGCG-3 0 . XbaI and BamHI sites were introduced at each end of the Epo enhancer. The synthesized Epo enhancer was annealed and ligated to produce multiple copies of the Epo enhancer. This ligated Epo enhancer was inserted upstream from the SV40 promoter at the BglII site. The VEGF 165 cDNA was amplified by PCR using pSG5-VEGF as a template. pSG5-VEGF was kindly provided by Dr Jozef Dulark (Jagiellonian University, Poland). The primers for PCR are forward primer 5 0 -CCCAAGCTTGAAACCAT GAACTTGCT-3 0 and backward primer 5 0 -GCTCTAGAT CATTCATTCATCACCGCCT-3 0 . The HindIII site was introduced to the forward primer (underlined), and the XbaI site was introduced to the backward primer (underlined). For PCR, the following reaction cycle was used: 30 cycles at 941C for 1 min, 551C for 1 min, and 721C for 1 min 30 s followed by an extension of 10 min at 721C. PCR products were digested with HindIII and XbaI. The VEGF cDNA was purified by 1.5% agarose gel electrophoresis and elution. The pSV-Luc (Promega, Madison, WI, USA) was digested with HindIII and XbaI and purified by 1.0% agarose gel electrophoresis and elution. The VEGF cDNA was inserted to the pSV-Luc plasmid. The construction of pSV-VEGF was confirmed by the restriction enzyme study. The Epo enhancer was inserted upstream from the SV40 promoter at the BglII site. The construction of pEpo-SV-VEGF was confirmed by the restriction enzyme study.
Synthesis of WSLP
WSLP was synthesized as described previously. 3 Briefly, PEI (1800 Da) was stirred on ice in a mixture of anhydrous methylene chloride and triethylamine for 30 min. Cholesteryl chloroformate was dissolved in methylene chloride and slowly added to the PEI solution. The mixture was stirred for 12 h on ice and the resulting product was dried on a rotary evaporator. The powder was dissolved in 0.1 N HCl. The aqueous solution was extracted with methylene chloride, and then filtered through a glass microfiber filter. The product was concentrated by solvent evaporation, precipitated with large excess acetone, and dried under a vacuum.
Cell culture and transfection
293 human embryonic kidney cells and HUVEC were obtained from ATCC (Rockville, MD, USA). It has been known that 293 cells do not have the endogenous VEGF protein.
14 293 cells were maintained in F-12K medium supplemented with 10% FBS, 2 mM L-glutamine, 1.5 mg/ ml sodium bicarbonate, and 0.1 mg/ml heparin, in a 5% CO 2 incubator. HUVEC were maintained in F-12K medium supplemented with 10% FBS, 2 mM L-glutamine, 1.5 mg/ml sodium bicarbonate, 0.1 mg/ml heparin, and 0.04 mg/ml endothelial cell growth supplement (ECGS) in a 5% CO 2 incubator.
For the transfection assays, the cells were seeded at a density of 5.0 Â 10 5 cells/well in six-well flat-bottomed microassay plates (Falcon Co., Becton Dickenson, Franklin Lakes, NJ, USA) 24 h before the transfection. The pDNA/WSLP complexes were prepared at a 40/1 N/P ratio, and incubated for 30 min at room temperature. The cells were washed twice with serum-free medium, and then 2 ml of fresh serum-free medium was added. The pDNA/WSLP complex was added to each well. The cells were then incubated for 4 h at 371C in a 5% CO 2 incubator. After 4 h, the transfection mixtures were removed and 2 ml of fresh medium containing FBS was added. The cells were incubated at the desired concentration of CoCl 2 or oxygen for 24 or 48 h. The cells and the media were harvested for luciferase assay, ELISA, and RT-PCR.
Luciferase assay
After incubation, the cells were washed with PBS twice, and 200 ml of reporter lysis buffer (Promega, Madison, WI, USA) was added to each well. After 15 min of incubation at room temperature, the cells were harvested and transferred to microcentrifuge tubes. After 15 s of vortexing, the cells were centrifuged at 11 k rpm for 3 min. The extracts were transferred to fresh tubes and stored at À701C until use. The protein concentrations of the extracts were determined by using BCA protein assay kit (Pierce, Iselin, NJ, USA). Luciferase activity was measured in terms of relative light units (RLU) using a 96-well plate Luminometer (Dynex Technologies Inc., Chantilly, USA). The luciferase activity was monitored and integrated over a period of 30 s. The final values of luciferase were reported in terms of RLU/mg total protein.
RT-PCR
Total RNA was prepared by acid-guanidium thiocyanate-phenol-chloroform extraction from the transfected cells as described previously, using RNAwiz (Ambion, Austin, TX, USA). 21 The total RNA was treated with RNase-free DNase I (Promega, Madison, WI, USA) to eliminate the contaminated DNA. The concentration of RNA was measured by the absorbance at 260 nm, and the integrity of RNA was confirmed by formaldehydeformamide denatured agarose gel electrophoresis. The total RNA (2 mg) was hybridized to the backward primer and reverse transcribed using AMV reverse transcriptase (Promega, Madison, WI, USA). The reverse-transcribed samples were amplified by PCR using Taq polymerase 0 -CACCGCCTCGGCTTGTCACAT-3 0 . The PCR reaction consisted of 941C for 3 min, 35 cycles at 941C for 30 s, 551C for 30 s, and 721C for 1 min, followed by an extension of 10 min at 721C. The PCR products were separated by electrophoresis in 1.5% agarose gels. The length of the expected product was 376 bp.
ELISA
ELISA was performed using ChemiKine human vascular endothelial growth factor sandwich ELISA kit (Chemicon, Temecular, CA, USA). In all, 100 ml of the sample was added into the designated wells; 25 ml of biotinylated rabbit anti-human VEGF polyclonal antibody was added to each well and the plate was incubated at room temperature for 3 h. After the incubation, the plate was washed five times with a wash buffer. Then, 50 ml of the streptavidin-alkaline phosphatase was added into each well and the plate was incubated at room temperature for 45 min. The substrate was added to the wells and the absorbance was measured at 490 nm.
In vitro endothelial cell proliferation assay
In vitro endothelial cell proliferation assay was performed as described previously.
14 The medium from the 293 cells transfected with pSV-VEGF or pEpo-SV-VEGF was collected, then added to ECGS-starved HUVEC plated in 24-well plates at a density of 4.0 Â 10 4 cells/ well. After 5 days, proliferation of the HUVEC was measured by MTT assay. After the incubation, 120 ml of 2 mg/ml MTT solution in PBS was added. The cells were incubated for an additional 4 h at 371C and then MTTcontaining medium was aspirated off and 750 ml of DMSO was added to dissolve the formazan crystal formed by live cells. Absorbance was measured at 570 nm.
Operative techniques and injection to the rabbit myocardium model
The operative technique was conducted as described previously. 22 Male New Zealand white rabbits weighing 2.5-3.0 kg were medicated with Ketamine (25 mg/kg) and Xylazine (4.4 mg/kg) prior to shaving the left chest. Isoflurane was administered via an endotracheal tube during the operation. The depth of anesthesia was adjusted by corneal reflex and muscle tone to an adequate level for the surgery. The small animal ventilator was set for a rate of 40 breaths/min and a volume of 30 ml, which was adjusted once the lungs were seen in order to fill the lungs with each breath.
The animal was prepped with isopropyl alcohol followed by dilute Betadine solution and then draped in a sterile fashion. A 22-gauge IV running Ringer's lactate at 20 ml/h was placed into a ear vein. A standard 3-4 cm left anterolateral thoracotomy allowed excellent exposure of the heart through the 4th intercostal space. For animals in the infarct group, the circumflex artery was ligated with a 6-0 Prolene suture. A carefully measured volume of injectate was given into the infarcted myocardium using a 30-gauge needle. The pneumothorax was evacuated prior to suture-closing the layers of the chest with absorbable suture. The rabbit was extubated once it was breathing appropriately. It was kept warm and given buprenorphine (0.05 mg/kg) for pain control.
The WSLP/plasmid complexes were prepared at a 10/1 N/P ratio as described previously. 5 The WSLP/ plasmid complex was injected to the left ventricles of the hearts. All injections were performed over 1 min in a subepicardial location with a fixed amount of plasmid (50 mg) in injectate volumes of 500 ml. The hearts were harvested 4 days after the injections and homogenized in lysis buffer (Promega, Madison, WI, USA). The transgene expression was measured by ELISA.
Statistical analysis
The comparison of VEGF concentration was made by Student's t-test. P-A value under 0.05 was thought to be statistically significant.
